Trending...
- Tacoma City Council Passes Ordinance 29086 Amending the Rental Housing Code and Landlord Fairness Code Initiative
- Naturism Resurgence (NRE) Announces the World's First Standardised Stigma Measure (SSM) for Naturism
- Spokane: Welding Sparks Ignite Multi-Business Fire on Holyoke Avenue
SEATTLE--(BUSINESS WIRE)--According to Coherent Market Insights, the global myeloproliferative neoplasm drugs market is estimated to be valued at US$ 8,379.5 million in 2020 and is expected to exhibit a CAGR of 3.9% over the forecast period (2020-2027).
Key Trends and Analysis:
The increasing incidence of myeloproliferative neoplasm is expected to drive growth of the global myeloproliferative neoplasm drugs market over the forecast period. According to the National Organization for Rare Disorders (NORD) 2020, men are more likely to be affected than women with polycythemia vera and this disorder is expected to affect around two people per 100,000 in the general population globally.
Moreover, the increasing number of pipeline products for the treatment of myeloproliferative neoplasm is expected to fuel growth of the global myeloproliferative neoplasm drugs market in the near future. For instance, on January 7, 2021, PharmaEssentia Corporation, a company focusing on research and development in biopharmaceutical industry, announced the initiation of investigational study phase 3 pivotal clinical trial of SURPASS ET, [Ropeginterferon Alfa-2b (P1101)]. SURPASS ET is a novel mono-pegylated proline interferon under evaluation for the treatment of the essential thrombocythemia (ET) type of myeloproliferative neoplasm (MPNs).
Among regions, North America is expected to register highest growth rate, owing to increasing number of pipeline products for the treatment of myeloproliferative neoplasm. For instance, in December 2020, AbbVie Inc. announced new data from the Phase 2 CAPTIVATE (PCYC-1142) clinical trial, evaluating IMBRUVICA (ibrutinib) in combination with VENCLEXTA/VENCLYXTO (venetoclax) in previously untreated patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), during an oral presentation session at the virtual 2020 American Society of Hematology (ASH) Annual Meeting.
More on Washingtoner
Request Sample Copy of this Research Report @
https://www.coherentmarketinsights.com/insight/request-sample/930
Key Market Takeaways:
The global myeloproliferative neoplasm drugs market is expected to exhibit a CAGR of 3.9% over the forecast period, as key players are focusing on strategies such as mergers and acquisitions in order to strengthen their position in the market. For Instance, in February 2020, F. Hoffmann-La Roche AG completely acquired Promedior, Inc., a clinical stage biotechnology company. As a result of this acquisition, F. Hoffmann-La Roche AG would obtain full rights to Promedior's entire portfolio of molecules for serious fibrotic diseases, including PRM-151.
Competitive Landscape:
Key players operating in the global myeloproliferative neoplasm drugs market include Novartis International AG, PharmaEssentia Corporation, Bristol - Myers Squibb, Pfizer, Inc., Takeda Pharmaceutical Company Limited, Incyte, Johnson & Johnson, Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche AG, Gamida Cell, Sierra Oncology, Inc., CTI BioPharma Corp., Imago BioSciences, AbbVie Inc., and Constellation Pharmaceuticals
Buy-Now this Research Report for detailed market insights @
https://www.coherentmarketinsights.com/insight/buy-now/930
Market Segmentation:
Related Market Intelligence Reports:
More on Washingtoner
Urinary Incontinence Treatment Drugs Market, by Incontinence Type (Urge Incontinence, Stress Incontinence, Over-flow Incontinence, Mixed Incontinence, and Other Type), by Drug Class (Anticholinergic/Antispasmodic Agents, Skeletal Muscle Relaxants, Antidepressants, Alpha Blockers, Topical Estrogens, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027
Read-more: https://www.coherentmarketinsights.com/market-insight/urinary-incontinence-treatment-drugs-market-4400
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide.
Key Trends and Analysis:
The increasing incidence of myeloproliferative neoplasm is expected to drive growth of the global myeloproliferative neoplasm drugs market over the forecast period. According to the National Organization for Rare Disorders (NORD) 2020, men are more likely to be affected than women with polycythemia vera and this disorder is expected to affect around two people per 100,000 in the general population globally.
Moreover, the increasing number of pipeline products for the treatment of myeloproliferative neoplasm is expected to fuel growth of the global myeloproliferative neoplasm drugs market in the near future. For instance, on January 7, 2021, PharmaEssentia Corporation, a company focusing on research and development in biopharmaceutical industry, announced the initiation of investigational study phase 3 pivotal clinical trial of SURPASS ET, [Ropeginterferon Alfa-2b (P1101)]. SURPASS ET is a novel mono-pegylated proline interferon under evaluation for the treatment of the essential thrombocythemia (ET) type of myeloproliferative neoplasm (MPNs).
Among regions, North America is expected to register highest growth rate, owing to increasing number of pipeline products for the treatment of myeloproliferative neoplasm. For instance, in December 2020, AbbVie Inc. announced new data from the Phase 2 CAPTIVATE (PCYC-1142) clinical trial, evaluating IMBRUVICA (ibrutinib) in combination with VENCLEXTA/VENCLYXTO (venetoclax) in previously untreated patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), during an oral presentation session at the virtual 2020 American Society of Hematology (ASH) Annual Meeting.
More on Washingtoner
- Children Rising Appoints Marshelle A. Wilburn as New Executive Director
- Fairmint CEO Joris Delanoue Elected General Director of the Canton Foundation
- Sleep Basil Mattress Co.'s Debuts New Home Page Showcasing Performance Sleep Solutions for Active Denver Lifestyles
- Bent Danholm Joins The American Dream TV as Central Florida Host
- The Nature of Miracles Celebrates 20th Anniversary Third Edition Published by DreamMakers Enterprises LLC
Request Sample Copy of this Research Report @
https://www.coherentmarketinsights.com/insight/request-sample/930
Key Market Takeaways:
The global myeloproliferative neoplasm drugs market is expected to exhibit a CAGR of 3.9% over the forecast period, as key players are focusing on strategies such as mergers and acquisitions in order to strengthen their position in the market. For Instance, in February 2020, F. Hoffmann-La Roche AG completely acquired Promedior, Inc., a clinical stage biotechnology company. As a result of this acquisition, F. Hoffmann-La Roche AG would obtain full rights to Promedior's entire portfolio of molecules for serious fibrotic diseases, including PRM-151.
Competitive Landscape:
Key players operating in the global myeloproliferative neoplasm drugs market include Novartis International AG, PharmaEssentia Corporation, Bristol - Myers Squibb, Pfizer, Inc., Takeda Pharmaceutical Company Limited, Incyte, Johnson & Johnson, Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche AG, Gamida Cell, Sierra Oncology, Inc., CTI BioPharma Corp., Imago BioSciences, AbbVie Inc., and Constellation Pharmaceuticals
Buy-Now this Research Report for detailed market insights @
https://www.coherentmarketinsights.com/insight/buy-now/930
Market Segmentation:
- Global Myeloproliferative Neoplasm Drugs Market, By Drug Class:
- Demethylation Agents
- Tyrosine kinase Inhibitor
- Multikinase Inhibitors
- JAK2 Inhibitor
- Others
- Global Myeloproliferative Neoplasm Drugs Market, By Indication:
- Ph+ Chronic myelogenous leukemia (CML)
- Ph- Myeloproliferative Neoplasms (MPNs)
- Myelofibrosis (MF)
- Polycythemia Vera (PV)
- Essential thrombocythemia (ET)
- Global Myeloproliferative Neoplasm Drugs Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Myeloproliferative Neoplasm Drugs Market, By Region:
- North America
- By Country:
- U.S.
- Canada
- By Country:
- Latin America
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- By Country:
- Europe
- By Country:
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- By Country:
- Asia Pacific
- By Country:
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- By Country:
- Middle East
- By Country/Region:
- GCC
- Israel
- Rest of Middle East
- By Country/Region:
- Africa
- By Country/Region:
- South Africa
- Central Africa
- North Africa
- By Country/Region:
- North America
Related Market Intelligence Reports:
More on Washingtoner
- Artificial Intelligence Leader Releases Children's Book on Veterans Day
- Felicia Allen Hits #1 Posthumously with "Christmas Means Worship"
- CCHR Documentary Probes Growing Evidence Linking Psychiatric Drugs to Violence
- Tokenized Real-World Assets: Iguabit Brings Institutional Investment Opportunities to Brazil
- MEX Finance meluncurkan platform keuangan berbasis riset yang berfokus pada data, logika, dan efisiensi pengambilan keputusan investasi
Urinary Incontinence Treatment Drugs Market, by Incontinence Type (Urge Incontinence, Stress Incontinence, Over-flow Incontinence, Mixed Incontinence, and Other Type), by Drug Class (Anticholinergic/Antispasmodic Agents, Skeletal Muscle Relaxants, Antidepressants, Alpha Blockers, Topical Estrogens, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027
Read-more: https://www.coherentmarketinsights.com/market-insight/urinary-incontinence-treatment-drugs-market-4400
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide.
0 Comments
Latest on Washingtoner
- IODefi Introduces New Web3 Infrastructure Framework as XRP Ledger Development Gains Global Attention
- Terizza Forms Strategic Collaboration with UC San Diego to Pioneer Next-Generation Distributed AI Infrastructure
- Tacoma: Hams for the Holidays – Ham Giveaway for Those in Need
- Spokane: Water Rescue Team Deployed to Western Washington Flood Emergency
- EnergyStrat Launches Global LNG Risk Outlook 2025–2030
- Strong Revenue Gains, Accelerating Growth, Strategic Hospital Expansion & Uplisting Advancements: Cardiff Lexington Corporation (Stock Symbol: CDIX)
- Holiday Decorations Most Likely to Cause Injuries
- UK Financial Ltd Confirms Official Corporate Structure of the Maya Preferred Project and Its Dual-Class Token System
- CCHR Florida Joins Global Call to Ban Electroshock Treatment, Citing New Evidence of Widespread Patient Harm
- BoxingRx Announces Full Gym Renovation Ahead of New Ownership's One-Year Anniversary
- UK Financial Ltd Announces It's Official Corporate Headquarters In The United Kingdom
- Ski Size Chart Launches Comprehensive Online Platform for Perfect Ski Selection
- Rigani Press Announces Breakthrough Book for Health IT and Medical Leaders to Forge the Road to Responsible AI
- FreeTo.Chat - The bold, Anonymous Confession Platform, ushers in a new era of tension relief
- Tacoma: Linnaea Jablonski Appointed City's New Human Resources Director
- Hyatt House Fresno Celebrates Grand Opening, Introducing the First Hyatt House in Fresno, California
- "I Make Music Not Excuses" Journal by Anthony Clint Jr. Becomes International Amazon Best Seller, Empowering Music Creators Worldwide
- Spokane: Tips To Help Prevent Package Theft This Holiday Season
- Spokane: Riverfront Park Holiday Village, Presented by Gesa Credit Union, Runs December 11-14
- DanReDev, Kaufman Development & Oldivai Announce Major 2026 Projects Nationwide